MANKIND

Mankind Pharma Ltd.

NSE: MANKIND

BSE: 543904

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

2,500.90+14.0 (+0.56%)

3 Jul, 9:59 AM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

91.3 / 100

Value Score

15.6 / 100

Price Momentum Score

79.4 / 100

QVM Score

73.4 / 100

Key Metrics

Market Cap

1,02,708 Cr

P/E (TTM)

53.69

P/B

6.30

P/S (TTM)

7.19

EV/EBITDA

29.51

CAPE (5Y)

58.98

ROE (TTM)

12.49

ROCE (TTM)

11.89

ROA (TTM)

6.85

Avg 3Y ROE

17.36

Earnings 3Y CAGR

13.09

Sales 3Y CAGR

17.73

Sales 5Y CAGR

18.10

Debt/Equity

0.39

Consensus TP

2734.50

Strong Buy %

22.22

Promoter Holding

72.66

Pledged %

0.00

Stock Analysis

Fundamental analysis overview of Mankind Pharma Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Strong price momentum

Price Momentum score of 79.4 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term

What is Price Momentum score?

79.4 / 100

High and stable operating margin

The company reported strong operating margin of 19.13% for 12-month ended 31 Mar 2026 and operating margin declined marginally by -50 bps from 1 year ago

What is Operating profit margin?

Moderate revenue growth and above median growth of industry

The company delivered moderate revenue growth of 16.96% for 12-month ended 31 Mar 2026 and the growth was 5.72 percentage points higher than median growth of industry

What is Sales growth (1Y)?

Median: 11.24

Value 16.96

-82.35114662

Low Debt to Equity, not much change from last year

The company has low Debt to Equity of 0.39 as on 31 Mar 2026 and Debt to Equity decreased marginally by 0.2 in the last 1 year

What is Debt to Equity?

Company's earnings are of high quality

Earnings quality score of 74.7 indicates that the company's earnings are of high quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

74.7 / 100

Negative

Expensive and at a premium to industry median P/E

PE TTM of 53.69 indicates that the stock is expensive on a standalone basis and is at a 77.43% premium to industry median P/E

What is P/E Ratio?

Median: 30.26

Value 53.69

-215.443183

Analysts have been downgrading forward EPS estimates

Analyst EPS estimate (consensus) for forward EPS has decreased by -1.57% in the last 3 months, indicating weak earnings momentum

What is Earnings upgrade (3M)?

Moderate ROE but declining trend

The company reported moderate ROE of 12.49% for 12-month ended 31 Mar 2026 but ROE declined by -430 bps from 1 year ago

What is ROE (FY)?

Low EPS growth and lower than median growth of industry

The company delivered moderate EPS growth of -5.7% for 12-month ended 31 Mar 2026 and the growth was 13.82 percentage points lower than median growth of industry

What is EPS growth (1Y)?

Low dividend yield

The company has a low dividend yield of 0.04%

What is Dividend yield?

Neutral

Not enough talking points with neutral stance

Financial Snapshot

See detailed analysis

Multi-year trends for Mankind Pharma Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Mankind Pharma Ltd. Shareholding Pattern

Quarterly breakdown of Mankind Pharma Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Sep 2013	Sep 2014	Sep 2015	Sep 2016	Sep 2017	Sep 2018	Aug 2019	Mar 2020	Mar 2021	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Promoter	10.77	10.77	89.00	89.00	89.00	89.00	79.00	79.00	79.00	76.50	76.50	76.50	76.51	74.88	74.87	74.87	72.71	72.70	72.68	72.67	72.66	72.66
Indian Promoter	-	10.77	89.00	89.00	89.00	89.00	79.00	79.00	79.00	76.50	76.50	76.50	76.51	74.88	74.87	74.87	72.71	72.70	72.68	72.67	72.66	72.66
Foreign Promoter	10.77	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-
Institutions	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.25	8.82	8.74	16.53	21.01	21.53	22.27	24.40	24.37	24.53	24.72	24.55	24.66
Mutual Funds / UTI	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.83	3.92	3.90	7.55	8.57	7.37	6.99	7.83	7.67	7.34	7.78	9.30	10.36
FI/Bank/Insurance	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.75	0.55	0.50	1.94	2.17	2.14	2.34	2.21	2.23	2.24	1.77	1.12	1.14
Govt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-
FII	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.61	4.18	4.18	6.74	9.87	11.58	12.37	13.34	12.92	13.07	12.83	11.34	10.24
Other Institutions	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.06	0.18	0.16	0.29	0.40	0.43	0.58	1.01	1.54	1.88	2.32	2.80	2.92
Non-Institution	89.23	89.23	11.00	11.00	11.00	11.00	21.00	21.00	21.00	18.25	14.68	14.76	6.97	4.11	3.61	2.86	2.90	2.93	2.79	2.61	2.79	2.68
Bodies Corporate	0.00	0.00	10.77	0.00	0.00	0.00	20.95	0.00	20.95	13.54	13.54	13.53	5.73	2.78	2.03	1.17	1.15	1.11	1.07	1.07	1.08	1.07
Others (incl. Retail) No. of shareholders	89.23 8	89.23 8	0.23 1	11.00 2	11.00 2	11.00 2	0.05 1	21.00 0	0.05 1	4.71 4,01,794	1.14 1,31,091	1.23 1,33,923	1.24 1,26,573	1.33 1,34,140	1.58 1,52,201	1.69 1,62,422	1.75 1,69,709	1.82 1,79,177	1.72 1,78,216	1.54 1,69,086	1.71 1,76,322	1.61 1,76,385

Holdings and Presence

Indices and prominent investors with a stake in this stock.

Index Presence

#	Index	Weight	Rank
1	Nifty Pharma	3.02%	13 / 20
2	Nifty Healthcare	2.59%	16 / 20
3	Nifty Midcap 50	1.2%	43 / 50
4	Nifty Midcap 100	0.81%	56 / 100
5	Nifty Midcap 150	0.67%	58 / 149
6	NIFTY Large Midcap 250	0.35%	95 / 250
7	Nifty 500	0.14%	148 / 499
8	Nifty Total Market	0.13%	155 / 749

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Mankind Pharma Ltd. shares as reported to NSE and BSE.

Name	Month	Transaction	Holding % pre transaction	Average price	Qty.	Transaction value
Arjun Juneja Promoter Group	February-2024	Block Deal (Disposal) 9th Feb 2024	2.64 %	₹ 2,107.35	24.01 lac	₹ 506.00 cr
Puja Juneja Promoter Group	February-2024	Block Deal (Disposal) 9th Feb 2024	3.45 %	₹ 2,107.35	22.71 lac	₹ 478.65 cr
Sheetal Arora Promoter	February-2024	Block Deal (Disposal) 9th Feb 2024	5.27 %	₹ 2,107.35	18.17 lac	₹ 382.92 cr

Corporate Actions

History of Mankind Pharma Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

Dividend₹ 1/share
Record date: 8th Aug 2025Ex-date: 8th Aug 2025
Announced on: 31st Jul 2025

Company Profile

Overview of Mankind Pharma Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Mankind Pharma Limited is an India-based pharmaceutical company. The Company is engaged in developing, manufacturing, and marketing a range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It also offers pet care, cro...

Key personnel

Mr. Ashutosh Dhawan

Global Chief Financial Officer

Mr. Prakash Agarwal

President - Strategy

Mr. Atish Majumdar

Senior President - Sales and Marketing

Dr. Birendra Singh

Senior President - Global Quality Head

Mr. Abhay Kumar Srivastava

Senior President - Operations

Mr. Arjun Juneja

Chief Operating Officer

Mr. Prateek Dubey

Global Chief Human Resource Officer

Mr. Suresh Raju Penmetsa

Chief Risk Officer and Senior Vice President - EHS

View all

Incorporated on

03 Jul 1991

Last Annual

31 Mar 2026

Last Interim

31 Mar 2026

No. of Employees

IPO date

09 May 2023

Free Float

10,16,10,409

Website

https://www.mankindpharma.com/

Phone no.

+911147476600

Address

262, Okhla Industrial Estate, Phase-III, NEW DELHI, 110020, India

Frequently Asked Questions

What is the current share price of Mankind Pharma Ltd.?

The current share price of Mankind Pharma Ltd. is ₹ 2,500.90 as of 3 Jul 2026.

What is the market capitalisation of Mankind Pharma Ltd.?

The market capitalisation of Mankind Pharma Ltd. stands at ₹ 1,02,708.00 Cr.

What is the PE ratio of Mankind Pharma Ltd.?

The Price-to-Earnings (PE) ratio of Mankind Pharma Ltd. is 53.69 as of the latest trailing twelve months data.

What is the ROE and ROCE of Mankind Pharma Ltd.?

Mankind Pharma Ltd. has a Return on Equity (ROE) of 12.49% and a Return on Capital Employed (ROCE) of 11.89% as per the latest financial reports.

What is the 52-week high and low of Mankind Pharma Ltd.?

The 52-week high of Mankind Pharma Ltd. is - and the 52-week low is -.

What is the dividend yield of Mankind Pharma Ltd.?

The dividend yield of Mankind Pharma Ltd. is 0.04% based on the current market price.

What is the FII and DII holding in Mankind Pharma Ltd.?

Foreign Institutional Investors (FII) hold 10.24%, Domestic Institutional Investors (DII) hold 11.50% and retail/public investors hold 1.61% of Mankind Pharma Ltd. shares.

What sector does Mankind Pharma Ltd. belong to?

Mankind Pharma Ltd. operates in the Healthcare sector. 61.11% of analysts have a Buy or Strong Buy rating on Mankind Pharma Ltd. with a consensus target price of ₹ 2,734.50, implying 9.96% upside from current levels.

What is the beta of Mankind Pharma Ltd.?

The beta of Mankind Pharma Ltd. is 0.72, indicating its price volatility relative to the broader market. Over the past 1 year, Mankind Pharma Ltd. has delivered an absolute return of 7.77%.

What is the RSI of Mankind Pharma Ltd.?

The 14-day Relative Strength Index (RSI) of Mankind Pharma Ltd. is 56.75, placing it in the neutral zone. An RSI above 70 is considered overbought and below 30 is considered oversold.

Mankind Pharma Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Mankind Pharma Ltd. Shareholding Pattern

Holdings and Presence

Bulk, Block and Insider Trades

Corporate Actions

Company Profile

Frequently Asked Questions

Corporate Actions

Holdings and Presence

Company Profile

Stock Analysis